Abstract

Inhaled corticosteroids (ICSs) are the mainstay of anti-inflammatory treatment in subjects with asthma and COPD. This review evaluates the role of nebulizers as an alternative to inhalers for delivering ICSs in asthma and COPD. I selected 16 randomized, placebo-controlled, blinded, long-term studies, mostly carried out in asthma (n = 14) and COPD. Nebulized budesonide has been demonstrated to be effective and safe in children ages 1-8 years, and, with less evidence, in infants and adults with asthma. Other investigations, with the addition of in vitro and in vivo comparison studies, have shown that nebulized beclomethasone, fluticasone, and flunisolide are effective alternatives to nebulized budesonide in asthma and COPD. Efficient delivery of nebulized ICSs requires that the nebulizer system, the nebulized drug formulation, and the inhaling subject interact properly. The practices of mixing nebulized ICSs with bronchodilators and using nebulized ICSs in acute settings are promising, but require further confirmations, and at present cannot be recommended. I conclude that nebulizers may be considered as an effective alternative to inhalers for delivering ICSs and can be recommended to asthmatic and COPD subjects who are unwilling or unable to use inhalers. Newer formulations could possibly offer a relevant advance for a more efficient nebulization of ICSs.

Links

Aggregator Full Text

Authors

Melani AS

Institution

Fisiopatologia e Riabilitazione Respiratoria, Policlinico Le Scotte, Azienda Ospedaliera Universitaria Senese, Siena, Italy. amelani@ao-siena.toscana.it

Source

Respiratory care 57:7 2012 Jul pg 1161-74

MeSH

Administration, Inhalation
Androstadienes
Asthma
Beclomethasone
Dose-Response Relationship, Drug
Equipment Design
Fluocinolone Acetonide
Glucocorticoids
Humans
Nebulizers and Vaporizers
Pulmonary Disease, Chronic Obstructive

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22272733